Osman Kibar: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 30: | Line 30: | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 21:07, 17 March 2025
Osman Kibar is a Turkish-American entrepreneur and scientist, best known as the founder and CEO of Samumed, a biopharmaceutical company focused on tissue regeneration.
Early Life and Education[edit]
Osman Kibar was born in Izmir, Turkey. He moved to the United States for his higher education, earning a Bachelor of Science degree in Electrical Engineering from California Institute of Technology (Caltech) and a Ph.D. in Optics from the University of California, San Diego (UCSD).
Career[edit]
After completing his Ph.D., Kibar co-founded Genoptix, a specialized laboratory service provider, which was later sold to Novartis for $470 million in 2011. He then founded Samumed, a company that aims to harness the regenerative power of the Wnt signaling pathway to reverse age-related degeneration and treat diseases such as osteoarthritis, baldness, and cancer.
Recognition[edit]
Kibar has been recognized for his contributions to the field of biotechnology. In 2016, he was named in the Forbes list of global billionaires, with an estimated net worth of $4 billion. He was also listed in the PharmaVOICE 100, a list of the most inspiring people in the life sciences industry.
See Also[edit]
References[edit]
<references />
External Links[edit]
